Holders of Biohit Oyj convertible bond sell loan back to company
Biohit Oyj
Stock exchange release
2 February 2012 10.15 a.m.
The holders of Biohit Oyj’s convertible bond have sold the loan back to the company.
On 28 October 2010, Biohit Oyj issued a convertible bond targeted at institutional investors. The value at the moment of issue was EUR 4.05 million. The fixed coupon rate of the bond is 6.5% and it has a five-year maturity. Each share of the loan of EUR 4,500 entitles the holder to exchange the share of the loan for 1,000 B shares with a nominal value of EUR 0.17. The rate of exchange of the share is EUR 4.5. The loan can be exchanged for a maximum of 900,000 Biohit Oyj shares.
Biohit Oyj paid the loan back to the holders of the convertible bond on 1 February 2012.
For further details, contact:
Semi Korpela
President and CEO
Tel. +358 40 573 7701
semi.korpela@biohit.fi
Distribution:
NASDAQ
OMX Helsinki Oyj
Central Storage Facility (www.oam.fi)
Press
www.biohit.fi
About Biohit
Biohit Oyj is a globally operating Finnish biotechnology company established in 1988. Biohit's mission crystallizes in its motto “Innovating for Health”. The company assumes social responsibility by producing innovations, new technologies and analysis systems for use in medicine, research institutions and industry. These products help to promote research and diagnostics, while improving quality of life by preventing disease, human suffering and financial loss. Biohit also seeks to innovate and develop the marketing and availability of its products and services, in order to ensure its profitable growth and ability to pay dividends.
Biohit works with scientific communities to produce new technologies, products and services based on research results and innovations. These can be used to develop safe and cost-effective diagnostic tests for the early detection and prevention of diseases of the gastrointestinal tract. (www.biohit.fi / International / State of the art GastroPanel and Acetium innovations for the unmet need)
Biohit's products include analysis systems for the prevention and early diagnosis of gastrointestinal diseases, such as the blood-sample based GastroPanel examinations for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and H. pylori infection in connection with gastroscopy, and the ColonView examination for the early detection of intestinal bleeding that indicates a risk of colorectal cancer. Acetium reduces the amount of carcinogenic acetaldehyde in an anacidic stomach. (www.acetium.com/test - reveals acetaldehyde exposure)
Biohit employs around 35 people. The company is headquartered in Helsinki, Finland and has a subsidiary in the UK. Since 1999, Biohit’s Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group and is traded under the code BIOBV (www.biohit.fi).
Read more at www.biohit.fi